Frontiers Comparative analysis of small molecule and growth factor derived human induced pluripotent stem cell derived hepatocyte like cells Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high risk HER2 positive early breast cancer (DESTINY Breast11): a randomised, open label, multicentre, phase III trial Annals of Oncology Frontiers Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure Evidence based selection of the starting dose in first in human clinical trials using humanized mouse models Clinical trial landscape for histone deacetylation inhibitors in breast cancer: a dawn in the darkness? Journal of Translational Medicine Springer Nature Link